Three Phase III trials launching simultaneously is a significant bet, but the more revealing number is the gap Boehringer Ingelheim is trying to close: survival outcomes in extrapulmonary neuroendocrine carcinoma have not meaningfully improved in decades, and the company is now moving its DLL3-targeted T-cell engager, obrixtamig, into late-stage development across two of the most intractable neuroendocrine carcinoma settings at once.
The two DAREON program trials, DAREON-Lung-1 and DAREON-NEC-1, are designed around DLL3 expression as a predictive biomarker, which is the central design decision worth scrutinizing. DLL3 is highly expressed on tumor cells in both extensive-stage small cell lung cancer and epNEC while largely absent from healthy tissue, making it a clean target in principle. In DAREON-Lung-1, obrixtamig is added to atezolizumab plus chemotherapy as a first-line combination in ES-SCLC patients. In DAREON-NEC-1, obrixtamig pairs with carboplatin and etoposide versus chemotherapy alone in DLL3-positive unresectable or metastatic epNEC. Both trials test combination backbone strategies, which reflects the reality that the first-line SCLC space is not static: the European Commission granted approval in June 2026 for lurbinectedin plus atezolizumab as a maintenance option in ES-SCLC, illustrating how quickly the standard of care is shifting beneath any Phase III program in this disease.
The third trial, Beamion LUNG-3, moves zongertinib into earlier disease territory: adjuvant monotherapy in stage II through IIIB HER2-mutant NSCLC patients who have already undergone complete surgical resection. Zongertinib received FDA accelerated approval in August 2025 for unresectable or metastatic HER2 TKD-mutant NSCLC, so this trial is an explicit push up the disease-stage ladder. The primary endpoint is disease-free survival, which is a harder outcome to move than overall response rate but a more persuasive one for a curative-intent setting where recurrence risk remains substantial after surgery.
What ties these three programs together is a commitment to biomarker selection as the enrollment filter, not a broad histology sweep. That design philosophy will either prove its worth or expose its limitation in the same moment: if the DLL3-high population in DAREON-NEC-1 is smaller than projected, enrollment pace becomes the trial’s defining constraint. Watch the screening failure rate from the epNEC cohort once interim enrollment data surface; that number will signal whether the biomarker strategy is commercially viable or scientifically sound but logistically fragile.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
